1. Home
  2. NVNI vs BIVI Comparison

NVNI vs BIVI Comparison

Compare NVNI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

N/A

Current Price

$0.89

Market Cap

10.9M

Sector

N/A

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

N/A

Current Price

$1.97

Market Cap

10.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVNI
BIVI
Founded
2019
2013
Country
Brazil
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
10.3M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
NVNI
BIVI
Price
$0.89
$1.97
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
37.6K
10.7M
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
74.83
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.67
N/A
Revenue Next Year
$26.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.82
52 Week High
$4.94
$3.79

Technical Indicators

Market Signals
Indicator
NVNI
BIVI
Relative Strength Index (RSI) 41.44 53.40
Support Level $0.77 $1.14
Resistance Level $1.28 $2.35
Average True Range (ATR) 0.08 0.30
MACD -0.01 0.00
Stochastic Oscillator 38.76 47.99

Price Performance

Historical Comparison
NVNI
BIVI

About NVNI Nvni Group Limited

Nvni Group Ltd, through its existing subsidiary companies, operates business-to-business software-as-a-service (B2B SaaS) products in Brazil, serving a diversified customer base of small and mid-sized enterprises across vertical markets. The Group's core business activity is providing a SaaS platform model focused on the software delivery method of cloud-based software applications to its customers. The Group generates revenues and profits from SaaS platform subscription services, data analytics services, set-up and other services. The Group has a single operating and reportable segment, multi-vertical SaaS solution model. The Group operates and generates revenue from Brazil.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: